Is that another IPO in the making? Ex-Novartis CEO Joe Jimenez and a lead Kite player take up new posts at an off-the-shelf rival to 2 pioneering drugs
Right on the heels of taking on a $160 million crossover round in a likely leap to Nasdaq, Century Therapeutics CEO Lalo Flores is now pushing ahead with the high-profile ex-Novartis chief Joe Jimenez as chairman.
Jimenez’s greatest fame at Novartis was earned for one of its weakest products, as their pioneering personalized CAR-T Kymriah won the honors for the first such drug to make it to the market. Now a host of players, including Century, are barreling in behind the frontrunners with allogeneic rivals that can be created for off-the-shelf use.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 148,200+ biopharma pros reading Endpoints daily — and it's free.